Research graph
References from Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis. Local targets link to admitted publications; unresolved targets remain external evidence.
Immunocompromised patients have been neglected in COVID-19 trials: a call for action.
10.1016/j.cmi.2022.05.005 · 2022 · External reference
Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.
10.1093/rheumatology/keaa897 · 2021 · External reference
COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study.
10.1002/art.41619 · 2021 · External reference
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study.
10.1016/s2665-9913(21)00401-x · 2022 · External reference
Factors associated with COVID-19-related death using OpenSAFELY.
10.1038/s41586-020-2521-4 · 2020 · External reference
American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5.
10.1002/art.42372 · 2023 · External reference
COVID-19 vaccination and antirheumatic therapy.
10.1093/rheumatology/keab223 · 2021 · External reference
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
10.1136/annrheumdis-2021-220647 · 2021 · External reference
Impact of immunomodulatory therapy on COVID-19 vaccine response in patients with autoimmune inflammatory rheumatic diseases.
10.3390/vaccines12030274 · 2024 · External reference
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
10.1016/s2665-9913(23)00298-9 · 2024 · External reference
Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis.
10.1038/s41541-024-00805-3 · 2024 · External reference
Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
10.1136/annrheumdis-2018-213222 · 2018 · External reference
A multicenter, prospective, randomized, parallel-group trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis.
10.1002/art.42318 · 2023 · External reference
The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 Vaccine—United States, December 2020.
10.15585/mmwr.mm6950e2 · 2020 · External reference
Master protocols to study multiple therapies, multiple diseases, or both.
10.1056/nejmra1510062 · 2017 · External reference
Generating real-world evidence from the excellence network in rheumatology.
10.1002/pds.70067 · 2024 · External reference
Content and construct validity, reliability, and responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 workshop report.
10.3899/jrheum.161145 · 2017 · External reference
PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions.
10.1016/j.jclinepi.2015.08.038 · 2016 · External reference
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.
10.1186/s12891-016-1082-z · 2016 · External reference
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
10.1136/annrheumdis-2021-220597 · 2021 · External reference
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
10.1016/s2213-2600(22)00186-2 · 2022 · External reference
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials.
10.1016/s2665-9913(22)00228-4 · 2022 · External reference
Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.
10.1016/j.cell.2020.05.015 · 2020 · External reference
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.
10.1038/s41577-020-0389-z · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
